Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vilmer

Showing results (221-230 of 240) with videos related to

Pageof 24
Sort By:
Leukemia|March 4, 2005
No prognostic effect of additional chromosomal abnormalities in children with acute lymphoblastic leukemia and 11q23 abnormalitiesA V Moorman, S C Raimondi, C H Pui, et al.
International Journal of Cancer|September 28, 2002
The kinetics of the visible growth of a primary melanoma reflects the tumor aggressiveness and is an independent prognostic marker: a prospective studyJean Jacques Grob, Marie Aleth Richard, Johany Gouvernet, et al.
Blood|May 16, 2000
Treatment outcome in infant acute lymphoblastic leukemia. Children Leukemia Cooperative Group--EORTC. European Organization for Research and Treatment of CancerA Ferster, Y Benoit, N Francotte, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1997
Systemic effect of intrathecal methotrexate during the initial phase of treatment of childhood acute lymphoblastic leukemia. The European Organization for Research and Treatment of Cancer Children's Leukemia Cooperative GroupA Thyss, S Suciu, Y Bertrand, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 16, 2004
Outcome of childhood acute promyelocytic leukemia with all-trans-retinoic acid and chemotherapyS de Botton, V Coiteux, S Chevret, et al.
Leukemia|September 2, 2005
Results of 58872 and 58921 trials in acute myeloblastic leukemia and relative value of chemotherapy vs allogeneic bone marrow transplantation in first complete remission: the EORTC Children Leukemia Group reportN Entz-Werle, S Suciu, J van der Werff ten Bosch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 3, 2001
Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trialF Millot, S Suciu, N Philippe, et al.
International Journal of Cancer|June 22, 2000
Delays in diagnosis and melanoma prognosis (I): the role of patientsM A Richard, J J Grob, M F Avril, et al.
Leukemia|March 4, 2005
Value of intravenous 6-mercaptopurine during continuation treatment in childhood acute lymphoblastic leukemia and non-Hodgkin's lymphoma: final results of a randomized phase III trial (58881) of the EORTC CLGJ van der Werff Ten Bosch, S Suciu, A Thyss, et al.
International Journal of Cancer|June 22, 2000
Delays in diagnosis and melanoma prognosis (II): the role of doctorsM A Richard, J J Grob, M F Avril, et al.
Pageof 24

Showing results (221-230 of 240) with videos related to

Sort By:
Pageof 24
Leukemia|March 4, 2005
No prognostic effect of additional chromosomal abnormalities in children with acute lymphoblastic leukemia and 11q23 abnormalitiesA V Moorman, S C Raimondi, C H Pui, et al.
International Journal of Cancer|September 28, 2002
The kinetics of the visible growth of a primary melanoma reflects the tumor aggressiveness and is an independent prognostic marker: a prospective studyJean Jacques Grob, Marie Aleth Richard, Johany Gouvernet, et al.
Blood|May 16, 2000
Treatment outcome in infant acute lymphoblastic leukemia. Children Leukemia Cooperative Group--EORTC. European Organization for Research and Treatment of CancerA Ferster, Y Benoit, N Francotte, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1997
Systemic effect of intrathecal methotrexate during the initial phase of treatment of childhood acute lymphoblastic leukemia. The European Organization for Research and Treatment of Cancer Children's Leukemia Cooperative GroupA Thyss, S Suciu, Y Bertrand, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 16, 2004
Outcome of childhood acute promyelocytic leukemia with all-trans-retinoic acid and chemotherapyS de Botton, V Coiteux, S Chevret, et al.
Leukemia|September 2, 2005
Results of 58872 and 58921 trials in acute myeloblastic leukemia and relative value of chemotherapy vs allogeneic bone marrow transplantation in first complete remission: the EORTC Children Leukemia Group reportN Entz-Werle, S Suciu, J van der Werff ten Bosch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 3, 2001
Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trialF Millot, S Suciu, N Philippe, et al.
International Journal of Cancer|June 22, 2000
Delays in diagnosis and melanoma prognosis (I): the role of patientsM A Richard, J J Grob, M F Avril, et al.
Leukemia|March 4, 2005
Value of intravenous 6-mercaptopurine during continuation treatment in childhood acute lymphoblastic leukemia and non-Hodgkin's lymphoma: final results of a randomized phase III trial (58881) of the EORTC CLGJ van der Werff Ten Bosch, S Suciu, A Thyss, et al.
International Journal of Cancer|June 22, 2000
Delays in diagnosis and melanoma prognosis (II): the role of doctorsM A Richard, J J Grob, M F Avril, et al.
Pageof 24